Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Humacyte Inc HUMAW


Primary Symbol: HUMA

Financial Services Healthcare Biotechnology
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to... see more

Current News (NDAQ:HUMA)

Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

GlobeNewswire 6 days ago

Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

GlobeNewswire January 8, 2026

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

GlobeNewswire January 5, 2026

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

GlobeNewswire December 22, 2025

Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

GlobeNewswire December 16, 2025

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV(TM)) Clinical Results

GlobeNewswire November 20, 2025

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

GlobeNewswire November 13, 2025

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 12, 2025

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

GlobeNewswire November 10, 2025
View More News ››

Opinion & Analysis (NDAQ:HUMA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:HUMA)

Sell buddy sell.

Otherwise you guys will be going down big-time today and tomorrow
coolfooldumbguy - March 26, 2025
View more Bullboard ››

Green Bridge Metals Corporation

Green Bridge Metals Corporation

Green Bridge Metals Corporation engages in the acquisition, exploration, and development of mining projects in Canada. The ...
View More »

Podcasts